Maribavir: Interim Phase II data

ViroPharma disclosed on its 1Q13 earnings call that interim data from 13 patients in a U.S. Phase II trial showed that twice-daily oral maribavir led to undetectable plasma CMV DNA in 92% of patients. One patient was withdrawn from treatment before clearing virus because of progression of underlying post-transplant complications that led to a decision to pursue comfort care only. The patient subsequently died. Maribavir was safe with taste disturbance reported as the most common adverse event. The trial is slated to enroll 120 patients who received hematopoietic stem cell or solid organ transplants who are resistant or refractory to prior anti-CMV treatment including ganciclovir, Valcyte valganciclovir or foscarnet to receive twice-daily 400, 800 or 1,200 mg maribavir for up to 12 weeks. ...